KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
Status: | Recruiting |
---|---|
Conditions: | Psychiatric, ADHD |
Therapuetic Areas: | Psychiatry / Psychology, Other |
Healthy: | No |
Age Range: | 6 - 12 |
Updated: | 4/22/2018 |
Start Date: | March 13, 2018 |
End Date: | March 2019 |
Contact: | Jenn Gargione |
Email: | jenn.gargione@premier-research.com |
Phone: | 267-536-3561 |
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
This study is a multicenter, dose-optimized, open-label safety study with KP415 in children
with Attention-Deficit/Hyperactivity Disorder (ADHD).
with Attention-Deficit/Hyperactivity Disorder (ADHD).
The study will consist of a Screening Period, a Dose Optimization Phase, and a Treatment
Phase and a Follow-Up Visit, as follows:
- Screening Period: Subjects will undergo a screening period up to 30 days prior to
entering the Dose Optimization Phase.
- Dose Optimization Phase: During the Dose Optimization Phase, subjects will be titrated
to doses of 20, 30 or 40 mg KP415 based on tolerability and best individual
dose-response in the opinion of the Investigator.
- Treatment Phase: Eligible subjects will receive single daily doses of KP415 for up to
approximately 360 days (up to approximately 12 months). The dose of KP415 given in the
Treatment Phase will be the dose of KP415 at the end of the Dose Optimization Phase.
During the Treatment Phase, the dose of KP415 may be changed based on individual
tolerability and best dose response (to either 20, 30, or 40 mg KP415 capsules). Safety,
efficacy and sleep behavior assessments will be performed.
- Follow-Up Visit: 3 ±2 days after administration of the last dose of the Treatment Phase,
subjects will enter a Follow-Up Visit to evaluate safety parameters.
Phase and a Follow-Up Visit, as follows:
- Screening Period: Subjects will undergo a screening period up to 30 days prior to
entering the Dose Optimization Phase.
- Dose Optimization Phase: During the Dose Optimization Phase, subjects will be titrated
to doses of 20, 30 or 40 mg KP415 based on tolerability and best individual
dose-response in the opinion of the Investigator.
- Treatment Phase: Eligible subjects will receive single daily doses of KP415 for up to
approximately 360 days (up to approximately 12 months). The dose of KP415 given in the
Treatment Phase will be the dose of KP415 at the end of the Dose Optimization Phase.
During the Treatment Phase, the dose of KP415 may be changed based on individual
tolerability and best dose response (to either 20, 30, or 40 mg KP415 capsules). Safety,
efficacy and sleep behavior assessments will be performed.
- Follow-Up Visit: 3 ±2 days after administration of the last dose of the Treatment Phase,
subjects will enter a Follow-Up Visit to evaluate safety parameters.
Inclusion Criteria:
1. Subject must meet Diagnostic and Statistical Manual of Mental Disorders - Fifth
Edition (DSM-5) criteria for a primary diagnosis of ADHD (combined, inattentive, or
hyperactive/impulsive presentation) per clinical evaluation and confirmed by the Mini
International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).
2. Subject must have a score of at least 3 (mildly ill) on the clinician-administered
Clinical Global Impressions-Severity (CGI-S) scale.
3. Subjects who completed the efficacy study with KP415 may be rolled over into the
current study.
4. Subject, subject's parent/legal guardian and caregiver (if applicable) must understand
and be willing and able to comply with all study procedures and visit schedule.
Exclusion Criteria:
1. Subject with any clinically significant chronic medical condition that may interfere
with the participant's ability to participate in the study.
2. Subject has any diagnosis of bipolar I or II disorder, major depressive disorder,
conduct disorder, obsessive-compulsive disorder, any history of psychosis, autism
spectrum disorder, disruptive mood dysregulation disorder (DMDD), intellectual
disability, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or
behavioral disturbances.
3. Subject has evidence of any chronic disease of the central nervous system (CNS) such
as tumors, inflammation, seizure disorder, vascular disorder, potential CNS related
disorders that might occur in childhood, or history of persistent neurological
symptoms attributable to serious head injury.
4. Subject has a current (last month) psychiatric diagnosis other than specific phobia,
motor skills disorders, oppositional defiant disorder, sleep disorders, elimination
disorders, adjustment disorders, learning disorders, or communication disorders.
Participants with school phobia or separation anxiety will not be eligible.
5. Subject has clinically significant suicidal ideation/behavior, based on a history of
attempted suicide and the C-SSRS assessment at Screening or at any time before the
last dose of study drug.
6. Subject has any clinically significant unstable medical abnormality, chronic disease,
or a history of a clinically significant abnormality of the cardiovascular,
gastrointestinal, respiratory, hepatic, or renal systems, or a disorder or history of
a condition that may interfere with drug absorption, distribution, metabolism, or
excretion of study drug.
7. Subject has a history or presence of abnormal ECGs.
We found this trial at
19
sites
Portland, Oregon 97210
Principal Investigator: Beal Essink, MD
Phone: 503-276-6224
Click here to add this to my saved trials
Austin, Texas 78731
Principal Investigator: Michael Downing, MD
Phone: 214-369-2600
Click here to add this to my saved trials
Berlin, New Jersey
Principal Investigator: Howard Hassman, MD
Phone: 856-753-7335
Click here to add this to my saved trials
Click here to add this to my saved trials
Canton, Ohio 44718
Principal Investigator: Shishuka Malhotra, MD
Phone: 330-493-1118
Click here to add this to my saved trials
Colorado Springs, Colorado 80910
Principal Investigator: Andrew Sedillo, MD
Phone: 719-634-6576
Click here to add this to my saved trials
Dayton, Ohio 45408
Principal Investigator: Otto Dueno, MD
Phone: 937-424-1050
Click here to add this to my saved trials
Houston, Texas 77024
Principal Investigator: Matthew Brams, MD
Phone: 832-251-7000
Click here to add this to my saved trials
Houston, Texas 77098
Principal Investigator: Alain Katic, MD
Phone: 713-527-8448
Click here to add this to my saved trials
Jacksonville, Florida 32216
Principal Investigator: Nandita Jones, MD
Phone: 904-281-5757
Click here to add this to my saved trials
Las Vegas, Nevada 89128
Principal Investigator: Ann Childress, MD
Phone: 702-838-0742
Click here to add this to my saved trials
Lauderhill, Florida 33319
Principal Investigator: Rishi Kakar, MD
Phone: 954-990-6326
Click here to add this to my saved trials
Libertyville, Illinois 60048
Principal Investigator: Michael Greenbaum, MD
Phone: 847-549-7214
Click here to add this to my saved trials
Little Rock, Arkansas 72211
Principal Investigator: Jim Aukstuolis, MD
Phone: 501-221-8681
Click here to add this to my saved trials
Maitland, Florida 32751
Principal Investigator: Andrea Marraffino, MD
Phone: 407-644-1165
Click here to add this to my saved trials
Memphis, Tennessee 38119
Principal Investigator: Valerie Arnold, MD
Phone: 901-843-1045
Click here to add this to my saved trials
Orlando, Florida 32806
Principal Investigator: Robert Molpus, MD
Phone: 407-425-5100
Click here to add this to my saved trials
Overland Park, Kansas 66211
Principal Investigator: William Murphy, MD
Phone: 913-438-8221
Click here to add this to my saved trials
Salem, Oregon 97301
Principal Investigator: Drissana Tran, MD
Phone: 503-540-0100
Click here to add this to my saved trials